PPP1R12A Antibody (Phospho-Thr853)

Polyclonal Antibody

Phosphorylated by CIT (Rho-associated kinase). Phosphorylated cooperatively by ROCK1 and CDC42BP on Thr-696. Phosphorylated on upon DNA damage, probably by ATM or ATR. In vitro, phosphorylation of Ser-695 by PKA and PKG appears to prevent phosphorylation of the inhibitory site Thr-696, probably mediated by PRKG1. Phosphorylation at Ser-445, Ser-472 and Ser-910 by NUAK1 promotes interaction with 14-3-3, leading to inhibit interaction with myosin light chain MLC2, preventing dephosphorylation of MLC2. May be phosphorylated at Thr-696 by DMPK; may inhibit the myosin phosphatase activity. Phosphorylated at Ser-473 by CDK1 during mitosis, creating docking sites for the POLO box domains of PLK1. Subsequently, PLK1 binds and phosphorylates PPP1R12A.

130 kDa

PPP1R12A

Liquid. PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

MYPT1 is a protein encoded by the PPP1R12A gene which is approximately 115, 2 kDa. MYPT1 is localised to the cytoplasm. It is involved in the activation of cAMP-dependent PKA, beta-adrenergic signalling, vascular smooth muscle contraction and actin nucleation by ARP-WASP complex. It regulates the interaction of actin and myosin downstream of the guanosine triphosphatase Rho and is also a key regulator of protein phosphatase 1C. MYPT1 is expressed in striated muscles, specifically in type 2a fibres. Mutations in the PPP1R12A gene may result in infratentorial cancer and medullomyoblastoma. STJ90822 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This primary antibody specifically binds to endogenous MYPT1 protein which only binds about T853 when T853 is phosphorylated.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Phospho-MYPT1 (T853) Polyclonal Antibody detects endogenous levels of MYPT1 protein only when phosphorylated at T853.